IOVA Iovance Biotherapeutics, Inc.
Legal ·
Iovance (Nasdaq: IOVA) and unnamed officers are defendants in a California class action over 2025 revenue guidance. Derivative suits against Frederick Vogt, Jean-Marc Bellemin and others are stayed. Iovance has moved to dismiss.
Iovance (Nasdaq: IOVA) is a nominal defendant in two Court of Chancery suits against its directors. A 2020 pay suit is consolidated and a 2024 offering suit is in motion-to-dismiss briefing.
The sale agreement supplement covers up to $89,650,167 of stock sold through Jefferies. Iovance's last reported sale price was $3.93 on June 17, 2026, and its 2025 net loss was $391.0 million.
Iovance may sell up to $350.0 million of stock through Jefferies, which can take up to 3.0% of gross proceeds. The company is not obliged to sell any shares, and its stock last traded at $2.60 on August 19, 2025.
A 24-month sublease with Vaxcyte at $99,549.53 per month replaces a lease with original monthly rent of $279,540.80.
Iovance Biotherapeutics develops and delivers tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumor cancers. Its commercial product, Amtagvi, is for previously treated advanced melanoma, and the company's top priority is to drive its commercial success through training and collaboration with healthcare professionals at academic and community authorized treatment centers. Its development pipeline includes TIL cell therapies and next generation approaches in additional solid tumor cancers, including one-time TIL monotherapies for previously treated patients and TIL cell therapy combined with standard of care in earlier treatment settings. Two registrational trials are ongoing in frontline advanced melanoma and previously treated advanced non-small cell lung cancer. The company planned to commence a registrational trial in previously treated advanced undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma in the second quarter of 2026. In the European Union, it withdrew its initial marketing authorization application in July 2025 and is working with the European Medicines Agency to resubmit a centralized application in 2026.
| Product or program | What it is | Stage |
|---|---|---|
| Amtagvi | TIL cell therapy for previously treated advanced melanoma | Commercial |
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $300.3 million | $276.2 million |
| Net income (loss) | -$391.0 million | -$372.2 million |
| Cash from operations | -$302.4 million | -$353.0 million |
| Cash and equivalents | $163.1 million | $115.7 million |
| Short-term investments | $133.9 million | $208.1 million |
Our latest story on this, dated Aug 6, 2026: "Iovance faces securities class action and three derivative suits over 2025 revenue forecast". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 6, 2026: "Iovance defends two Delaware derivative suits over director pay and a 2024 stock offering". The story links the filing or release it is based on. Read the story.
Iovance Biotherapeutics, Inc. trades under the ticker IOVA on NASDAQ.
Iovance Biotherapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: BX:IOVA; DUS:2LB; FWB:2LB; GETTEX:2LB; HAM:2LB; HAN:2LB; LS:A2DT49; LSE:0JDK; LSX:A2DT49; MUN:2LB; SWB:2LB; TRADEGATE:2LB; XETR:2LB.
The SEC Central Index Key (CIK) for Iovance Biotherapeutics, Inc. is 1425205. Its filings are on SEC EDGAR.
452,971,432 shares as of 2026-07-29, per the cover page of its 10-Q filed 2026-08-06.
Our directory records Iovance Biotherapeutics, Inc. under United States.
Our directory classifies Iovance Biotherapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Iovance Biotherapeutics, Inc. is US4622601007.
aibio.space lists Iovance Biotherapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Iovance Biotherapeutics develops and delivers tumor-infiltrating lymphocyte (TIL) cell therapy for solid tumor cancers. Its commercial product, Amtagvi, is for previously treated advanced melanoma, and the company's top priority is to drive its commercial success through training and collaboration with healthcare professionals at academic and community authorized treatment centers.
Amtagvi: TIL cell therapy for previously treated advanced melanoma Stage: Commercial.
Iovance Biotherapeutics, Inc. reported a net loss of $391.0 million for the fiscal year ended Dec 31, 2025, and used $302.4 million of cash in operations, per its annual report to the SEC.
$300.3 million in the fiscal year ended Dec 31, 2025, per its annual report.
Set up an at-the-market program to sell shares over time. SEC Form S-3ASR. Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01,9.01). Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported a financing. SEC Form 424B5. Source
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-Q. Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio